Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has been given a consensus recommendation of “Hold” by the six brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $21.67.
A number of brokerages have recently issued reports on CRVS. ValuEngine downgraded Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Tuesday, November 7th.
Several large investors have recently made changes to their positions in CRVS. New York State Common Retirement Fund increased its holdings in shares of Corvus Pharmaceuticals by 2,269.1% in the 2nd quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after acquiring an additional 9,099 shares during the period. SG Americas Securities LLC purchased a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at $150,000. Alliancebernstein L.P. purchased a new position in Corvus Pharmaceuticals during the 2nd quarter worth $175,000. California State Teachers Retirement System grew its stake in Corvus Pharmaceuticals by 121.2% during the 2nd quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock worth $181,000 after buying an additional 8,200 shares during the last quarter. Finally, Teachers Advisors LLC grew its stake in Corvus Pharmaceuticals by 338.4% during the 2nd quarter. Teachers Advisors LLC now owns 15,568 shares of the company’s stock worth $188,000 after buying an additional 12,017 shares during the last quarter. Institutional investors and hedge funds own 84.84% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3224460/corvus-pharmaceuticals-inc-crvs-given-consensus-rating-of-hold-by-brokerages.html.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.